View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Bo...

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and In...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports S...

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Second Quarter Results ATLANTA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its second quarter of fiscal 2025 ended August 2, 2025. Consolidated net sales in the second quarter of fiscal 2025 were $403 million compared to $420 million in the second quarter of fiscal 2024. EPS on a GAAP basis was $1.12 compared to $2.57 in the second quarter of fiscal 2024. On an adjusted basis, EPS was $1.26 compared to $2.77 in the second quarter of fiscal 2024. Tom Chubb...

 PRESS RELEASE

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Glob...

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executi...

 PRESS RELEASE

Tron Inc. Expands TRX Treasury with $110,000,000 New Investment from L...

Tron Inc. Expands TRX Treasury with $110,000,000 New Investment from Largest Shareholder 312.5 Million TRX Tokens Worth $110 Million Added to TreasuryOver $220 Million in TRX HoldingsMajority Shareholder Increases Total Investment to $210 Million Winter Park, Florida, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tron Inc. (Nasdaq: TRON) (the “Company”), an innovation leader at the intersection of blockchain, entertainment, and digital assets, today announced the expansion of its TRON (TRX) token treasury holdings to over $220 million. The increase comes from Bravemorning Limited (“Bravemorning”),...

 PRESS RELEASE

Oxford to Release Second Quarter Fiscal 2025 Results on September 10, ...

Oxford to Release Second Quarter Fiscal 2025 Results on September 10, 2025 ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE: OXM) today announced that it plans to release its second quarter fiscal 2025 financial results after the market close on Wednesday, September 10, 2025. Following the news release, the company will also hold a conference call starting at 4:30 p.m. ET, hosted by Thomas C. Chubb lll, Chairman, Chief Executive Officer, and President, and K. Scott Grassmyer, Executive Vice President, Chief Financial Officer, and Chief Operating Officer, to discuss...

Modine Manufacturing Co: 1 director

A director at Modine Manufacturing Co sold 25,173 shares at 140.862USD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 20, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for N...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (G...

 PRESS RELEASE

Tron Inc. Reports Record Second Quarter Financial Results

Tron Inc. Reports Record Second Quarter Financial Results -Over $111,000,000 in Shareholders’ Equity- Largest TRX Holdings of Any Public Company Winter Park, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tron Inc. (Nasdaq: TRON) (the “Company”), an innovation leader at the intersection of blockchain, entertainment and digital assets announced financial results for the fiscal quarter ending on June 30, 2025, in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on Friday. The Company reported net income of $1,467,855 for the three months ended June 30, 2025, compare...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch